IQVIA Holdings Inc. (BVMF:I1QV34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 146.18B -4.4% |
| Revenue (ttm) | 86.76B +7.3% |
| Net Income | 7.23B +3.8% |
| EPS | 42.11 +9.9% |
| Shares Out | n/a |
| PE Ratio | 20.23 |
| Forward PE | 13.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Average Volume | 130 |
| Open | 217.14 |
| Previous Close | 207.06 |
| Day's Range | 217.14 - 217.14 |
| 52-Week Range | 197.21 - 322.29 |
| Beta | 1.18 |
| RSI | 45.76 |
| Earnings Date | May 5, 2026 |
About IQVIA Holdings
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers ... [Read more]
Financial Performance
In 2025, IQVIA Holdings's revenue was $16.31 billion, an increase of 5.87% compared to the previous year's $15.41 billion. Earnings were $1.36 billion, a decrease of -0.95%.
Financial numbers in USD Financial StatementsNews
IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Holdings Transcript: Bank of America Global Healthcare Conference 2026
Q1 results exceeded expectations with strong growth in both commercial and RDS segments, supported by robust demand and AI-driven productivity. AI adoption is accelerating across top pharma clients, driving new offerings and operational efficiencies. Capital deployment favors buybacks, with ongoing M&A activity and increased investment in AI initiatives.
IQVIA Q1 Earnings Call Highlights
IQVIA NYSE: IQV reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing accelerating organic growth across its Commercial Solutions and R&D Solut...
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA CFO to Speak at Bank of America Health Care Conference 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA Holdings Earnings Call Transcript: Q1 2026
Record Q1 revenue and EPS exceeded guidance, driven by strong organic growth in both Commercial and R&D Solutions, robust AI adoption, and a record backlog. Full-year guidance was reaffirmed and EPS outlook raised, with continued strong demand and constructive market conditions.
IQVIA Holdings Earnings release: Q1 2026
IQVIA Holdings released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
IQVIA Holdings Slides: Q1 2026
IQVIA Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
IQVIA Holdings Quarterly report: Q1 2026
IQVIA Holdings has published its Q1 2026 quarterly earnings report on May 5, 2026.
IQVIA Reports First-Quarter 2026 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA to Announce First-Quarter 2026 Results on May 5, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life Sciences
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced...
IQVIA Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
AI is driving revenue and margin growth, with over 150 agents deployed and plans for 500+ by 2027. Demand is strong, especially in biotech, which is expanding into clinical and commercial stages. Recent acquisitions enhance drug discovery capabilities, while productivity programs and automation support margin expansion.
IQVIA Holdings Transcript: Leerink Global Healthcare Conference 2026
AI is driving efficiency and new revenue streams, supported by proprietary data and advanced agent deployment. Market stability has returned post-COVID, with biotech and large pharma fueling growth. The Cedar Gate acquisition enhances US patient analytics and real-world evidence capabilities.
IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA Releases its 2025 Sustainability Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sci...
IQVIA Holdings Proxy statement: Proxy Filing
IQVIA Holdings filed a proxy statement on February 27, 2026, providing details for shareholder voting and corporate governance matters.
IQVIA Holdings Proxy statement: Proxy Filing
IQVIA Holdings filed a proxy statement on February 27, 2026, providing details for shareholder voting and corporate governance matters.
IQVIA Holdings Transcript: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day
Strong Q4 growth and stable margins were reported, with Commercial Solutions and R&DS segments showing momentum. AI is seen as a major opportunity, leveraging proprietary data and new agentic solutions, while only minor consulting areas face risk. Leadership transition emphasizes continuity and optimism for future growth.
IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the li...
IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA forecasts weak annual profit on higher interest expenses
Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall Street expectations, weighed down by higher interest costs, even as strong fourth-quarter re...